País: Sudáfrica
Idioma: inglés
Fuente: South African Health Products Regulatory Authority (SAHPRA)
Schering
PROVIRON TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): PROVIRON TABLETS Oral androgen for the treatment of male patients COMPOSITION 1 tablet contains mesterolone (17beta-hydroxy-1alpha-methyl-5alpha-androstan-3-one) 25 mg and the preservatives methylparaben (0,02%) and propylparaben (0,01%). PHARMACOLOGICAL CLASSIFICATION A. 21.7 Male sex hormones. PHARMACOLOGICAL ACTION Proviron balances a deficiency of androgen formation which begins to fall gradually with increasing age. Therefore, Proviron is suitable for treatment of all conditions caused by deficient endogenous androgen formation. In the recommended therapeutic dosage, Proviron will not impair spermatogenesis. Proviron is especially well tolerated by the liver. INDICATIONS • Declining physical activity and mental alertness in middle- and old-aged men Reduced efficiency, easy fatigability, lack of concentration, weak memory, disturbances of libido and potency, irritability, disturbances of sleep, depressive moods, and general vegetative complaints are often attributed to androgen- deficiency. These complaints can be overcome or improved by the use of Proviron tablets. • Potency disturbances Proviron overcomes potency disturbances due to androgen-deficiency. It may also be of use as supplementary therapy in cases of diminished potency where androgen-deficiency is not the primary cause. • Hypogonadism Growth, development and function of androgen-dependent target organs are stimulated by Proviron. It promotes development of secondary male sex characteristics in cases of prepuberal hypogonadism. Full clinical and laboratory investigations are necessary in all cases of young patients prior to commencement of treatment. Proviron tablets may also be used as a substitution therapy in cases whe Leer el documento completo